Unity Biotechnology, Inc. (UBX) News
Filter UBX News Items
UBX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
UBX News Highlights
- UBX's 30 day story count now stands at 3.
- Over the past 6 days, the trend for UBX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NOV are the most mentioned tickers in articles about UBX.
Latest UBX News From Around the Web
Below are the latest news stories about UNITY BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate UBX as an investment opportunity.
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. “Following positive efficacy and safety data at 48 weeks from a single injection of UBX1325 (foselutoclax) in patients with diabetic macular edema, we are working to quickly and efficiently advance UBX1325 (foseluto |
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross ProceedsSOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,143,000 shares of common stock, having an exercise price of $8.50 per share, issued by UNITY on August 22, 2022, at a reduced e |
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging PicksHere are the best longevity stocks to consider. |
20 Foods Consumed By Longest Living People Every DayIn this article, we will be taking a look at the 20 foods consumed by longest living people every day. If you are not interested in the details about market insights on longevity, head straight to the 5 Foods Consumed By Longest Living People Every Day. The pursuit of longevity and vitality has captivated humankind […] |
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular DegenerationPatients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monotherapy at study start maintained visual acuity through 24 weeks and had only a 1.5 letter decrease from baseline at week 48 40% of UBX1325-treated patients did not require anti-VEGF treatment through 48 weeks and 64% |
Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 SharesOn September 14, 2023, Anirvan Ghosh, the CEO of Unity Biotechnology Inc (NASDAQ:UBX), sold 1,246 shares of the company's stock. |
20 States With The Longest Life Expectancy In AmericaIn this article, we will be taking a look at the 20 states with the longest life expectancy in America. If you want to skip our detailed analysis of companies that are working on improving life expectancy, you can go directly to see the 5 States With The Longest Life Expectancy In America. Life Expectancy […] |
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business UpdatesSOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We are focused on rapidly advancing UBX1325 (foselutoclax) into the next clinical study to help patients suffering from diabetic macular edema who receive suboptimal benefit from the current anti-VEGF standard of care, |
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel senolytic therapeutic candidate to be evaluated head-to-head against standard of care anti-VEGF in DME SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging |